Save up -80% on Pimavanserin
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Nuplazid
|$2,769||60 tablets/17 mg|
|Price with discount in nearest pharmacy. Price may vary.|
We offer free Pimavanserin coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Pimavanserin every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Pimavanserin volume of distribution
Average volume of distribution for pimavanserin following a single dose is 2,173L.12 Pimavanserin is 95-percent protein bound in human plasma. … To a lesser degree, pimavanserin is also metabolized via CYP2J2, CYP2D6, and other CYP and flavin-containing monooxygenase (FMO) enzymes.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Pimavanserin
Pimavanserin (ACP-103), marketed under the trade name Nuplazid, is a drug developed by Acadia Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A, with 40x selectivity over 5-HT2C, and no significant affinity or activity at 5-HT2B or dopamine receptors. As of September 3, 2009, pimavanserin has not met expectations for Phase III clinical trials for the treatment of Parkinson’s disease psychosis, and is in Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication. It is expected to improve the effectiveness and side effect profile of antipsychotics. The results of a clinical trial examining the efficacy, tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012 and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improve the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms. On September 2, 2014, the United States Food and Drug administration granted Breakthrough Therapy status to Acadia’s New Drug Application for pimavanserin.
Pimavanserin mechanism of action
ACP-103 reduces haloperidol-induced akathisia, a debilitating extrapyramidal side effect (EPS), in patients with schizophrenia. ACP-103 is a 5-HT2A inverse agonist, to reduce the side effects associated with antipsychotic drug treatment with haloperidol. ACP-103 reduced both the motor disturbances and hyperprolactinemia, a condition of elevated prolactin secretion, caused by haloperidol treatment.
Dosage forms of Pimavanserin
|Tablet, coated||oral||17 mg/1|
Acadia Pharmaceuticals Inc
Humans and other mammals
Indication of Pimavanserin
Investigated for use/treatment in neurologic disorders, parkinson’s disease, psychosis, schizophrenia and schizoaffective disorders, and sleep disorders.
Toxicity of Pimavanserin
No data are available regarding pimavanserin-induced major congenital malformations, miscarriage, or other birth defects in humans. In animal studies, no developmental effects were observed when oral pimavanserin was administered at up to 10 or 12 times the maximum recommended human dose (MRHD) of 34 mg daily to rats and rabbits, respectively. However, maternal toxicity and lower pup survival and body weight were reported following administration of two times the MRHD of pimavanserin to pregnant rats during pregnancy and lactation.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Pimavanserin on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.